TAF11: Potential Drug Targets Or Biomarkers for Various Diseases

Target Name: TAF11

NCBI ID: G6882

TAF11

TAF11: Potential Drug Targets Or Biomarkers for Various Diseases

TAF11 (Tissue Analysis of the Eye 11) is a protein that is expressed in various tissues of the body, including the eye, brain, and heart. It is a member of the TAF11 family, which includes several similar proteins that are involved in various cellular processes in the body. One of the key functions of TAF11 is its role in the development and maintenance of the blood-brain barrier, which is a specialized barrier that separates the brain from the surrounding blood vessels and helps to protect the brain from harmful substances.

Recent studies have suggested that TAF11 may be a drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because TAF11 is involved in several important cellular processes that are disrupted in these conditions, and may provide a useful target for therapeutic intervention.

One of the potential mechanisms by which TAF11 may be involved in cancer is its role in the development of drug resistance. Many cancer cells are able to evade the effects of chemotherapy and other forms of cancer treatment by regulating the activity of the blood-brain barrier. TAF11 is involved in the regulation of this barrier, and may play a key role in the development of cancer resistance.

In addition, TAF11 has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of characteristic symptoms, and are often treated with drugs that target the affected proteins. TAF11 may be a potential target for these conditions as well, as it is involved in the regulation of the blood-brain barrier and may be involved in the progression of neurodegeneration.

Another potential mechanism by which TAF11 may be involved in autoimmune disorders is its role in the regulation of immune cell function. Many autoimmune disorders involve the misregulation of the immune system, in which T cells and other immune cells become aberrantly active and cause inflammation and damage to body tissues. TAF11 is involved in the regulation of the activity of immune cells, and may play a key role in the development and progression of autoimmune disorders.

In conclusion, TAF11 is a protein that is expressed in various tissues of the body and is involved in several important cellular processes, including the development and maintenance of the blood-brain barrier, the regulation of drug resistance, the development and progression of neurodegenerative diseases, and the regulation of immune cell function. These functions make TAF11 a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of TAF11 in these conditions and to develop effective treatments.

Protein Name: TATA-box Binding Protein Associated Factor 11

Functions: The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription (PubMed:33795473). TFIID recognizes and binds promoters with or without a TATA box via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC) (PubMed:33795473). The TFIID complex consists of TBP and TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 (PubMed:33795473). TAF11, together with TAF13 and TBP, play key roles during promoter binding by the TFIID and TFIIA transcription factor complexes (PubMed:33795473)

The "TAF11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAF11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets